Literature DB >> 29617934

Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy.

Stephanie R Harrison1, Alice Tew2, Neil Steven3,4, Benjamin A Fisher1,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29617934     DOI： 10.1093/rheumatology/key080

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  3 in total

1.  Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma.

Authors:  Timothy P DiPeri; Mehmet Demirhan; Daniel D Karp; Siqing Fu; David S Hong; Vivek Subbiah; Joann Lim; Leomar Y Ballester; Jean H Tayar; Maria E Suarez-Almazor; Milind Javle; Funda Meric-Bernstam
Journal:  J Immunother Precis Oncol       Date:  2022-02-04

2.  Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.

Authors:  Harish Seethapathy; Meghan D Lee; Ian A Strohbehn; Orhan Efe; Nifasha Rusibamayila; Donald F Chute; Robert B Colvin; Ivy A Rosales; Riley M Fadden; Kerry L Reynolds; Ryan J Sullivan; Howard L Kaufman; Kenar D Jhaveri; Meghan E Sise
Journal:  Nephrol Dial Transplant       Date:  2022-02-25       Impact factor: 5.992

3.  Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment.

Authors:  Suzanne W van Landingham; Diane Puccetti; Heather Potter; David Gamm; Eli L Diamond; Mark J Lucarelli
Journal:  Am J Ophthalmol Case Rep       Date:  2020-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.